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18F-AV-1451 in Parkinson’s Disease 
with and without dementia and in 
Dementia with Lewy Bodies
Ruben Smith  1,2, Michael Schöll  2,3, Elisabet Londos2,4, Tomas Ohlsson5 & Oskar Hansson2,4
Mixed pathologies of α-synuclein, β-amyloid and tau are relatively common in Parkinson’s disease (PD) 
and Dementia with Lewy Bodies (DLB). We therefore wanted to study the retention patterns of 18F-AV-
1451 in PD, PD-dementia (PDD), and DLB. To do this 44 healthy controls, 11 non-demented patients 
with PD, 18 patients with PDD, and six patients with DLB underwent MRI and 18F-AV-1451 PET scanning 
and cognitive testing. We found that parietal 18F-AV-1451 retention was increased in patients with 
DLB compared to controls and PD patients, while 18F-AV-1451 uptake was reduced in the substantia 
nigra in PDD. Increased parietal 18F-AV-1451 PET uptake was associated with impaired performance 
on verbal fluency tests, and the decreased uptake in the substantia nigra correlated with worse motor 
function. We found no effect of the monoamine oxidase B inhibitor rasagiline on 18F-AV-1451 binding. In 
conclusion DLB patients have increased parietal 18F-AV-1451 uptake. Increased parietal tau is associated 
with executive impairment in patients with synucleinopathies, while decreased uptake in the substantia 
nigra is associated with parkinsonism. Further, our data indicate that 18F-AV-1451 does not significantly 
bind to MAO-B in vivo.
A large proportion of patients with Parkinson’s Disease (PD) eventually develop cognitive impairment and 
dementia1. In patients with Dementia with Lewy Bodies (DLB), cognitive decline should by definition precede 
or occur within one year of the appearance of motor symptoms2. Neuropathologically, the two diseases exhibit 
Lewy bodies in the neocortex, in limbic structures and in the brainstem, as well as loss of midbrain dopaminergic 
cells3–5. Further, coincidental AD pathology is also relatively common in PD and common in DLB5,6. 18F-AV-1451 
has been demonstrated to bind to paired helical filament (PHF)-tau aggregates7,8. We hypothesised that cortical 
retention of 18F-AV-1451 would be increased in the subjects affected by dementia compared to the non-demented 
controls and sought to investigate the usefulness of this PET-tracer in the diagnostic work-up for these different 
disorders.
In addition to tau aggregates, AV-1451 has been shown to bind to neuromelanin in the substantia nigra7,9,10. 
This binding was reduced in patients with PD and PD with mild cognitive impairment compared to controls11. 
To study whether the levels are reduced in PDD and DLB, and if they correlate with motor function, we assessed 
18F-AV-1451 retention in substantia nigra in our study participants.
Study participants and Methods
Participants. Informed written consent was obtained from all patients before inclusion in the study. All pro-
cedures were approved by the Regional ethics committee at Lund University, the Radiation protection committee 
at Skåne University Hospital, and the Swedish Medical Products Agency. All experiments were performed in 
accordance with relevant guidelines and regulations. The study participants were recruited from the Neurology 
and Memory clinics at Skåne University Hospital, Sweden as part of the ongoing Swedish BioFINDER study 
(www.biofinder.se). Controls within the BioFINDER-study were enrolled from the prospective Malmö Diet 
and Cancer study cohort12. We included 29 patients with PD diagnosed according to the National Institute of 
Neurological Disorders and Stroke (NINDS) diagnostic criteria for PD13, out of which 18 patients fulfilled criteria 
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for PD with dementia14; six patients with DLB according to the McKeith et al.-criteria15; and 44 neurologically 
healthy, age-matched controls.
Lumbar puncture was performed and cerebrospinal fluid (CSF) collected and handled as previously 
described16. The patients were assessed with Hoehn and Yahr staging17, UPDRS part III18, and by neurologic 
examination through a physician experienced in movement disorders. Patients were assessed on medication. 
Further, all study participants were tested cognitively by a registered nurse on an occasion separate to the imag-
ing. Cognitive tests used were: Mini-Mental State Exam19, letter S- and animal fluency20, A Quick Test for cogni-
tive speed (AQT)21, and the wordlist delayed recall part of the Alzheimer’s Disease Assessment Scale-cognitive 
Subscale (ADAS-cog)22. Amyloid positivity was defined as either 18F-Flutemetamol composite score >1.4223 or 
CSF β-Amyloid42 <550 pg/ml (clinical reference cut-off).
Image acquisition and processing. MRI. T1-weighted magnetization-prepared rapid gradi-
ent echo (MPRAGE) and Fluid-attenuated inversion recovery (FLAIR) images were acquired for all patients 
on a 3 T Siemens Skyra scanner (Siemens Medical Solutions, Erlangen, Germany) and processed along with 
the PET images using an in-house developed pipeline, described previously8 (for sequence details please see 
Supplementary Methods).
PET. The radiosynthesis procedure, radiochemical purity, and scanning methods for 18F-AV-1451 have been 
described in detail previously24. Subjects underwent a simplified protocol including one 18F-AV-1451 scan 
80–100 min (4 × 300 s frames) post injection on a GE Discovery 690 PET scanner (General Electric Medical 
Systems, Milwaukee, WI, USA). PET data was processed using an in-house developed pipeline described earlier8, 
using FreeSurfer 5.3 segmentation of the MRI, and standardized uptake value ratio (SUVR) calculation using the 
inferior cerebellar grey matter as reference region. SUVR values derived from the FreeSurfer-segmented regions 
of interest (ROIs) were pooled into larger composite ROIs (frontal; medial and lateral parietal; medial, inferior 
and lateral temporal; and occipital cortex) for further analysis. The exact composition of these ROIs is described 
in the Supplementary Methods. Ligand retention in the basal ganglia was analyzed separately using Pmod 3.711 
(PMOD technologies llc; Zürich, Switzerland) to replicate the method used in9. Input images were the SUVR 
images in MNI space derived from the above-mentioned imaging pipeline. Template ROIs for the substantia 
nigra as well as the globus pallidus were drawn on an MRI in atlas space, and the individual PET images were then 
coregistered to the MRI with the fusion tool. Volume of distribution (Vd) was calculated as previously described9.
Statistics. Statistical analyses were performed using IBM SPSS statistics for Macintosh, version 23. For 
comparisons between groups ANCOVA was used, adjusted for age. Chi-square tests were used to compare 
non-continuous variables (gender and amyloid positivity). T-tests were used to compare AV-1451 uptake in 
relation to MAO-B inhibitor intake. Correlations in Fig. 1 and Supplementary Figure 2 were performed using 
Pearson correlations. Finally, linear regression models adjusted for age and clinical diagnosis were performed. 
Statistical significance was assumed at p < 0.05.
AV-1451 uptake patterns were further compared between respective patient groups and control subjects 
employing a voxel-wise two-sample t-test as implemented in SPM12 (http://www.fil.ion.ucl.ac.uk/spm) adjusted 
for age. The results were thresholded at p < 0.01, uncorrected for multiple comparisons regarding the limited sam-
ple size. All AV-1451 SUVR images had been transformed into common Montreal Neurological Institute (MNI) 
space by using transformation measures from warping the co-registered MRI scans into the 2 mm MNI152 MRI 
template and smoothed with an 8 mm full width at half maximum (FWHM) kernel prior to the analysis.
Results
Participants. Study participants were recruited from the Neurology and Memory clinics at Skåne University 
Hospital, Sweden. We found no differences in gender, proportion of amyloid positive subjects, or education 
between the groups. PD patients were slightly younger than the other participants. As expected patients with 
PDD or DLB performed worse on cognitive testing compared to the other groups. All clinical characteristics are 
presented in Table 1.
Cortical retention of AV-1451. We observed increased 18F-AV-1451 retention in the medial and lat-
eral parietal lobes of patients with DLB compared to controls (p < 0.01) and non-demented patients with PD 
(p < 0.01) (Fig. 1, Supplementary Figure 1). In the medial areas of the parietal lobe we found increased uptake in 
PDD compared to PD (p < 0.05; Fig. 1). In the inferior temporal lobes a slightly lower retention of AV-1451 was 
seen in the PD-group compared to controls and PDD, but no other differences were observed (Supplementary 
Figure 2). No differences were observed between groups in other brain regions (p > 0.05; Fig. 1). Furthermore, we 
found no effect of amyloid positivity on AV-1451 SUVR in subjects with synucleinopathies (p > 0.05).
Next, we studied the associations between cognitive function and 18F-AV-1451 retention in the cortical areas 
of the included patients with synucleinopathies (PD, PDD and DLB). Significant correlations were found for 
Letter S fluency scores and tracer retention in both the medial and lateral parietal regions (r = −0.45; p < 0.01 
and r = −0.38; p < 0.05 respectively. Figure 1E,F). Similar results were obtained for animal fluency (r = −0.49; 
p < 0.01 and r = −0.42; p < 0.05). All effects remained statistically significant after correcting for age and diag-
nostic groups. The data were not corrected for multiple comparisons. No correlations were seen with cortical 
retention of AV-1451 and MMSE.
Since it had been reported that an MAO-B inhibitor reduced uptake of the tau PET-tracer 18F-THK535125, 
and more recently not affected retention of 18F-AV-145126, we compared 18F-AV-1451 retention in our study 
participants treated with the MAO-B inhibitor rasagiline (n = 7) with those without this medication (n = 22). 
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Figure 1. 18F-AV-1451 retention in cortical and subcortical regions. 18F-AV-1451 SUVRs in the frontal cortex 
(A), medial parietal cortex (B), lateral parietal cortex (C) and occipital cortex (D). Amyloid positive subjects are 
represented by red shapes and amyloid negative subjects by black shapes. Correlations of medial (E) and lateral 
(F) parietal cortex SUVRs to Letter S-fluency scores. PD = blue squares; PDD = black triangles; DLB = green 
inverted triangles. (G) The effect of MAO-B inhibition on SUVRs in the globus pallidus. (H) 18F-AV-1451 
SUVRs in the substantia nigra. (I) Correlation of 18F-AV-1451 SUVRs in the substantia nigra and the Unified 
Parkinson’s Disease Rating Scale (UPDRS) motor score. (J) Lateral and medial view of average SUVR images 
of the diagnostic groups studied. The rightmost column represents an average SUVR image of typical AD-
cases (n = 41) that have been included merely for visual comparison. White color in the AD images represents 
saturation of the SUVR-scale (i.e. SUVR > 2). Ctrl - controls; DLB - Dementia with Lewy Bodies; Inh - 
inhibitor; MAO-B - monoamine oxidase B; PD - Parkinson’s Disease; PDD - Parkinson’s Disease with dementia; 
Vd – Volume of distribution. *p < 0.05, **p < 0.01, ***p < 0.001.
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We observed no differences in the cortical or subcortical retention of 18F-AV-1451 between these two groups 
(p > 0.05; Fig. 1G).
Retention in the substantia nigra and the globus pallidus. Next, we evaluated 18F-AV-1451 retention 
in the substantia nigra. We found no difference between controls and non-demented PD participants, however, a 
significant decrease could be observed when comparing PDD to all other groups (Fig. 1H). The decrease in SUVR 
in the substantia nigra in subjects with PD/PDD/DLB correlated with an increase in the UPDRS motor scale 
(r = −0.46; p < 0.01; Fig. 1I). This remained statistically significant after correcting for age and diagnostic groups.
We have previously reported off-target AV-1451 binding that increases with age in the globus pallidus in 
controls and in patients with progressive supranuclear palsy27. In this study we observed no difference between 
groups in the globus pallidus after adjusting for age (data not shown). However, as expected, we found a strong 
correlation between 18F-AV-1451 retention in the globus pallidus and age (Supplementary Figure 2).
Discussion
We report slightly, yet significantly increased retention of 18F-AV-1451 in the parietal cortex of patients with DLB 
when compared to non-demented PD patients and controls. The increase in parietal AV-1451 uptake in DLB was 
clearly lower than retention levels typically seen in Alzheimer’s disease. While our results are largely in agreement 
with two recently published articles showing subtle increases in AV-1451 uptake in parietal regions in DLB cases, 
these studies did also report increased uptake in inferior and lateral temporal lobes28 as well as in large parts of 
the occipital lobes29, which we could not confirm in the current study. Possibly this could be attributed to the 
selection of controls for the studies. In the previously published studies28,29, controls were selected to be amyloid 
negative, whereas in the present study controls were included irrespective of amyloid status. Our results however, 
did not change substantially when excluding the amyloid positive controls or amyloid positive subjects over all. 
Another possible explanation to the differences between the studies may be the limited number of DLB cases in 
the present study. Even though we found increased retention of AV-1451 in the parietal lobes of DLB patients, 
the overlap between the diagnostic groups were substantial and the clinical usefulness of the tracer in differential 
diagnosis of PD and DLB is likely limited. Further, the retention of the ligand is low in DLB, and since neuro-
pathological correlates of AV-1451 retention and tau pathology is currently lacking in DLB, we cannot exclude 
that the signal detected may be related to general neurodegeneration and not to tau pathology per se.
Verbal fluency tests have been suggested to be sensitive to detect cognitive deficits in DLB5. In the present 
study, we found statistically significant associations between AV-1451 uptake in the parietal cortex and both 
letter S fluency and animal fluency, but not with memory function (word list delayed recall) or global cognition 
(MMSE). Kantarci and colleagues did not find an association between cognitive function and AV-1451 uptake in 
DLB. They did, however, not explore associations with fluency or other tests reflecting cognitive speed or execu-
tive function29. Gomperts et al. report correlations to MMSE with retention of AV-1451 in the inferior temporal 
gyrus28, a finding that we could not replicate in the current study. The cortical retention of AV-1451 in DLB and 
PDD is low, especially comparing to the levels of retention seen in AD (Fig. 1j). The correlations between AV-1451 
and cognitive decline are sparse in our PDD and DLB cases. Taken together, we believe that other pathologies 
than tau are responsible for the larger part of the cognitive decline seen in the PDD and DLB subjects.
In the present study, we found no increase in AV-1451 retention in the cortex of PD patients irrespective 








(n = 6) Significant differences
Disease duration (yr) N/A 5.1 ± 4.0 9.0 ± 4.1 5.5 ± 2.2 PD < PDD*
Age 76 ± 5.3 67 ± 5.5 73 ± 7.0 71 ± 6.3 PD < PDD*, C > PD***, C > PDD*
Gender (M/F) 21/23 8/3 12/6 3/3 n.s.
Aβ-status (positive/negative) 13/31 1/8§ 4/12§ 1/3§ n.s.
UPDRS III N/A 11 ± 8 27 ± 13 26 ± 21 PD < PDD**
MMSE 29 ± 1 28 ± 2 22 ± 4 22 ± 7 C > PDD***, C > DLB***, PD > PDD***, PD > DLB***
Education 11.7 ± 3.8 11.9 ± 2.8 12.3 ± 4.4 10.5 ± 2.8 n.s.
AQT (CS) 64.7 ± 12.5 68.5 ± 15.3 149.5 ± 73.5 89.0 ± 30.3 C < PDD***, PD < PDD***, PDD > DLB**
Word list delayed recall (ADAS) 2.3 ± 1.8 1.8 ± 1.4 6.5 ± 2.9 7.7 ± 2.9 C < PDD***, C < DLB***, PD < PDD***, PD < DLB***
Letter S-fluency 16 ± 7 15 ± 5 9 ± 3 9 ± 5 C > PDD***, C > DLB**, PD > DLB*, PD > PDD**
Animal fluency 24 ± 6 22 ± 6 11 ± 6 12 ± 8 C > PDD***, C > DLB***, PD > PDD***, PD > DLB**
Table 1. Clinical characteristics of study participants. Aβ - Amyloid beta; ADAS - Alzheimer’s Disease 
Assessment Scale; AQT (CS) - A Quick Test for cognitive speed (Colour and shape); N/A - Not applicable; 
MMSE - Mini-mental State Exam; UPDRS III – Unified Parkinson’s Disease Rating Scale, item III (motor score). 
n.s. – not significant. *p < 0.05, **p < 0.01, ***p < 0.001. §Data on amyloid status are missing on two subjects in 
the PD, PDD and DLB groups.
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of AV-1451 in a relatively large sample of non-demented PD patients11. Comparable results were also reported 
from another study in non-demented PD patients30. Moreover, decreased AV-1451 retention has previously been 
reported for the substantia nigra in PD and PD with mild cognitive impairment, potentially reflecting the loss of 
neuromelanin containing cells9,30. We found similar results in our study, observing decreased AV-1451 retention 
in the substantia nigra of PDD patients compared to controls. Furthermore, we could for the first time show that 
the decreased AV-1451 uptake in the substantia nigra correlated significantly with more pronounced parkinson-
ism according to UPDRS-III. No difference in the AV-1451 uptake in substantia nigra was observed between con-
trols and PD subjects, this could possibly be due to too small group sizes. The decrease in substantia nigra signal 
is also affected by disease duration (Suppl Fig. 2c). Since PD subjects have a shorter disease duration than PDD 
subjects this may in part explain the absence of a difference between controls and the non-demented PD group.
The MAO-B inhibitor selegiline has been demonstrated to block binding of the tau PET tracer THK535125. 
However, selegiline or rasagiline, was recently reported not to affect the retention of AV-145126. A small number 
(n = 7) of the participants in this study were on treatment with the MAO-B inhibitor rasagiline (none on sele-
giline). We did not observe any difference in the AV-1451 retention in the cerebral cortex, the globus pallidus, or 
the substantia nigra in these subjects when compared to participants not taking the drug. The data on MAO-B 
inhibition presented in Fig. 1 depicts SUVR-values. Similar findings were obtained using SUVs to account for 
potential MAO-B expression in the cerebellum. The number of patients on rasagiline in this comparison was low, 
and our data acquired in a cross-sectional manner, which renders any conclusion preliminary. Nonetheless, the 
results are in line with another recently published study26 and these result potentially suggests lower affinity of 
AV-1451 to MAO-B than THK5351.
In previous publications, we and others have reported age-related off-target binding in the globus pallidus in 
control subjects and patients with Progressive Supranuclear Palsy (PSP)27,31–34. Here, we found no effect of age 
on the retention of AV-1451 in any brain region except for the globus pallidus where age and pallidal AV-1451 
SUVRs were highly correlated (Suppl Fig. 2). This could potentially reflect an age-dependent iron accumulation31.
Limitations: One limitation of the study is the limited number of cases with DLB included. The results for DLB 
subjects should be interpreted with this in mind. Further, due to the exploratory nature of the study no correction 
for multiple comparisons was applied to the data. The main results of SUVRs in different brain regions would 
survive a correction for multiple comparisons except PD vs PDD in the medial parietal cortex and PD vs PDD 
and PDD vs DLB in the substantia nigra. The correlations of cognitive fluency tests to AV-1451 retention do not 
survive correction for multiple comparisons.
In conclusion, we report increased SUVRs in the parietal lobes of patients with DLB compared to healthy 
control and non-demented PD participants. In addition, parietal AV-1451 retention correlated with worse perfor-
mance on verbal fluency tests in patients with synucleinopathies. Decreased substantia nigra AV-1451 uptake was 
associated with more pronounced parkinsonism. Finally, the MAO-B inhibitor rasagiline did not affect retention 
of AV-1451.
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